Celyad Oncology S.A.
CYAD
Classifica tra le azioni
#31680
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Prezzo delle azioni
$0.24909259
Capitalizzazione di mercato
$11.77M
Variazione (1 giorno)
1.94%
Variazione (1 anno)
-14.21%
Paese
BE
Scambia Celyad Oncology S.A. (CYAD)
Categoria
Healthcare
Rapporto P/S per Celyad Oncology S.A. (CYAD)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Celyad Oncology S.A., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Celyad Oncology S.A. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| Non abbastanza dati per le date fornite. | ||
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
